214 related articles for article (PubMed ID: 21617701)
1. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.
Pike-Overzet K; Rodijk M; Ng YY; Baert MR; Lagresle-Peyrou C; Schambach A; Zhang F; Hoeben RC; Hacein-Bey-Abina S; Lankester AC; Bredius RG; Driessen GJ; Thrasher AJ; Baum C; Cavazzana-Calvo M; van Dongen JJ; Staal FJ
Leukemia; 2011 Sep; 25(9):1471-83. PubMed ID: 21617701
[TBL] [Abstract][Full Text] [Related]
2. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
[TBL] [Abstract][Full Text] [Related]
3. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
[TBL] [Abstract][Full Text] [Related]
4. Partial correction of immunodeficiency by lentiviral vector gene therapy in mouse models carrying
Castiello MC; Di Verniere M; Draghici E; Fontana E; Penna S; Sereni L; Zecchillo A; Minuta D; Uva P; Zahn M; Gil-Farina I; Annoni A; Iaia S; Ott de Bruin LM; Notarangelo LD; Pike-Overzet K; Staal FJT; Villa A; Capo V
Front Immunol; 2023; 14():1268620. PubMed ID: 38022635
[TBL] [Abstract][Full Text] [Related]
5. Partial reconstitution of V(D)J rearrangement and lymphocyte development in RAG-deficient mice expressing inducible, tetracycline-regulated RAG transgenes.
Shockett PE; Zhou S; Hong X; Schatz DG
Mol Immunol; 2004 Jan; 40(11):813-29. PubMed ID: 14687938
[TBL] [Abstract][Full Text] [Related]
6. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
7. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
[TBL] [Abstract][Full Text] [Related]
8. The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins.
Noordzij JG; de Bruin-Versteeg S; Verkaik NS; Vossen JM; de Groot R; Bernatowska E; Langerak AW; van Gent DC; van Dongen JJ
Blood; 2002 Sep; 100(6):2145-52. PubMed ID: 12200379
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.
Capo V; Castiello MC; Fontana E; Penna S; Bosticardo M; Draghici E; Poliani LP; Sergi Sergi L; Rigoni R; Cassani B; Zanussi M; Carrera P; Uva P; Dobbs K; Sacchetti N; Notarangelo LD; van Til NP; Wagemaker G; Villa A
J Allergy Clin Immunol; 2018 Sep; 142(3):928-941.e8. PubMed ID: 29241731
[TBL] [Abstract][Full Text] [Related]
10. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of RAG-2-/- mice: sustained correction of the immunodeficiency.
Yates F; Malassis-Séris M; Stockholm D; Bouneaud C; Larousserie F; Noguiez-Hellin P; Danos O; Kohn DB; Fischer A; de Villartay JP; Cavazzana-Calvo M
Blood; 2002 Dec; 100(12):3942-9. PubMed ID: 12393742
[TBL] [Abstract][Full Text] [Related]
12. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.
Garcia-Perez L; van Eggermond M; van Roon L; Vloemans SA; Cordes M; Schambach A; Rothe M; Berghuis D; Lagresle-Peyrou C; Cavazzana M; Zhang F; Thrasher AJ; Salvatori D; Meij P; Villa A; Van Dongen JJM; Zwaginga JJ; van der Burg M; Gaspar HB; Lankester A; Staal FJT; Pike-Overzet K
Mol Ther Methods Clin Dev; 2020 Jun; 17():666-682. PubMed ID: 32322605
[TBL] [Abstract][Full Text] [Related]
13. Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients.
Lagresle-Peyrou C; Benjelloun F; Hue C; Andre-Schmutz I; Bonhomme D; Forveille M; Beldjord K; Hacein-Bey-Abina S; De Villartay JP; Charneau P; Durandy A; Fischer A; Cavazzana-Calvo M
Mol Ther; 2008 Feb; 16(2):396-403. PubMed ID: 18223550
[TBL] [Abstract][Full Text] [Related]
14. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
15. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.
Ng YY; Baert MR; Pike-Overzet K; Rodijk M; Brugman MH; Schambach A; Baum C; Hendriks RW; van Dongen JJ; Staal FJ
Leukemia; 2010 Sep; 24(9):1617-30. PubMed ID: 20574453
[TBL] [Abstract][Full Text] [Related]
16. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.
Benjelloun F; Garrigue A; Demerens-de Chappedelaine C; Soulas-Sprauel P; Malassis-Séris M; Stockholm D; Hauer J; Blondeau J; Rivière J; Lim A; Le Lorc'h M; Romana S; Brousse N; Pâques F; Galy A; Charneau P; Fischer A; de Villartay JP; Cavazzana-Calvo M
Mol Ther; 2008 Aug; 16(8):1490-9. PubMed ID: 18560421
[TBL] [Abstract][Full Text] [Related]
17. Successful RAG1-SCID gene therapy depends on the level of RAG1 expression.
Pike-Overzet K; Baum C; Bredius RG; Cavazzana M; Driessen GJ; Fibbe WE; Gaspar HB; Hoeben RC; Lagresle-Peyrou C; Lankester A; Meij P; Schambach A; Thrasher A; Van Dongen JJ; Zwaginga JJ; Staal FJ
J Allergy Clin Immunol; 2014 Jul; 134(1):242-3. PubMed ID: 25117803
[No Abstract] [Full Text] [Related]
18. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer.
Mostoslavsky G; Fabian AJ; Rooney S; Alt FW; Mulligan RC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16406-11. PubMed ID: 17062750
[TBL] [Abstract][Full Text] [Related]
19. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.
Mortellaro A; Hernandez RJ; Guerrini MM; Carlucci F; Tabucchi A; Ponzoni M; Sanvito F; Doglioni C; Di Serio C; Biasco L; Follenzi A; Naldini L; Bordignon C; Roncarolo MG; Aiuti A
Blood; 2006 Nov; 108(9):2979-88. PubMed ID: 16835374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
